Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03629054
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Registration Number
- NCT03504566
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
- Conditions
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 175
- Registration Number
- NCT03429543
- Locations
- 🇺🇸
Children's Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Atlanta Center, Atlanta, Georgia, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Real World Glycemic Effectiveness of Linagliptin
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11001
- Registration Number
- NCT03338803
- Locations
- 🇺🇸
Optum, Eden Prairie, Minnesota, United States
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Interventions
- Drug: AtezolizumabDrug: DocetaxelDrug: RO6958688Drug: CPI-444Drug: LinagliptinDrug: Sacituzumab GovitecanDrug: BevacizumabDrug: CamonsertibDrug: CobimetinibDrug: IpatasertibDrug: PemetrexedDrug: EvolocumabDrug: TiragolumabOther: RadiationDrug: TocilizumabDrug: CarboplatinDrug: GemcitabineDrug: XL092
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT03337698
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan
A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Yanbing Li
- Target Recruit Count
- 232
- Registration Number
- NCT03320031
- Locations
- 🇨🇳
endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- Conditions
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT03281369
- Locations
- 🇺🇸
Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States
🇺🇸Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇦🇺Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT03259490
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT03011177
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 207
- Registration Number
- NCT02974504
- Locations
- 🇰🇷
Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.